Effective sensitization of temozolomide by ABT-888 is lost with development of TMZ resistance in glioblastoma xenograft lines

Resistance to temozolomide (TMZ) and radiotherapy (RT) is a major problem for patients with GBM but may be overcome using the PARP-inhibitor ABT-888. Using two primary GBM xenografts, the efficacy of ABT-888 combined with RT and/or TMZ was evaluated. Treatment with ABT-888 combined with TMZ resulted...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Clarke, Michelle J., Mulligan, Evan A., Grogan, Patrick T., Mladek, Ann C., Carlson, Brett L., Schroeder, Mark A., Curtin, Nicola J., Lou, Zhenkun, Decker, Paul A., Wu, Wenting, Plummer, E. Ruth, Sarkaria, Jann N.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2692390/
https://ncbi.nlm.nih.gov/pubmed/19174557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-08-0854
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk